Therapeutic options for targeting inflammatory osteoarthritis pain
Published May 8, 2019 · P. Conaghan, A. Cook, J. Hamilton
Nature Reviews Rheumatology
247
Citations
8
Influential Citations
Abstract
Pain is the major symptom of osteoarthritis (OA) and is an important factor in strategies to manage this disease. However, the current standard of care does not provide satisfactory pain relief for many patients. The pathophysiology of OA is complex, and its presentation as a clinical syndrome is associated with pathologies of multiple joint tissues. Inflammation is associated with both OA pain and disease outcome and is therefore a major treatment target for OA and OA pain. Unlike TNF inhibitors and IL-1 inhibitors, established drugs such as glucocorticoids and methotrexate can reduce OA pain. Although central nociceptive pathways contribute to OA pain, crosstalk between the immune system and nociceptive neurons is central to inflammatory pain; therefore, new therapies might target this crosstalk. Newly identified drug targets, including neurotrophins and the granulocyte–macrophage colony-stimulating factor (GM-CSF)–CC-chemokine ligand 17 (CCL17) chemokine axis, offer the hope of better results but require clinical validation.Pain management is presently the focus of osteoarthritis (OA) therapy, but traditional pain-relieving drugs such as NSAIDs and glucocorticoids have limited utility. In this Review, the next generation of OA analgesics and their potential mechanisms of action are discussed.Key pointsOsteoarthritis (OA) pain is a financial, physical and psychological burden globally.Inflammation is often associated with OA pain and the development of OA.Pathological changes in central nociceptive pathways contribute to OA pain.Bidirectional crosstalk between the immune and nervous systems regulates OA pain.New therapeutics that target inflammation and the crosstalk between the immune and nervous systems are being developed to prevent and treat OA pain.